$29.51
-0.05 (-0.17%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RCUS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
32 interventional
Held by 14 tracked-famous managers (CITADEL ADVISORS LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, Hudson Bay Capital Management LP, Man Group plc, +9 more) · FINRA short interest 11.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT06608927Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine | Metastatic Pancreatic Ductal Adenocarcinoma | 610 | 2030-11-30 | in 1,564 d | 2026-07-31 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsNCT05536141Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab | Clear Cell Renal Cell Carcinoma, Solid Tumors | 362 | Mar 2029 | ≤ 955 d | 2026-07-29 |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Casdatifan, Cabozantinib, Placebo | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | 720 | Apr 2028 | ≤ 620 d | 2026-07-31 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | Sep 2027 | ≤ 407 d | 2026-07-30 |
| A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesNCT04104672Number of participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine | Advanced Pancreatic Cancer | 196 | May 2027 | ≤ 285 d | 2026-07-02 |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 169 | May 2027 | ≤ 285 d | 2026-07-29 |
| Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic FunctionNCT07751250Area under the concentration time curve, from time 0 to the last observed non-zero concentration, of casdatifan in plasma (AUC0-t)Non-randomized · Open-label · Basic science | Phase 1 | Not yet recruiting | Drug: Casdatifan | Healthy Participants, Hepatic Impairment | 16 | May 2027 | ≤ 285 d | 2026-08-07 |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766Number of Participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Gastrointestinal Tract Malignancies | 332 | Jan 2027 | ≤ 165 d | 2026-07-29 |
| A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy ParticipantsNCT07662057Number of participants experiencing Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Not yet recruiting | Drug: AB102 · Other: Placebo | Healthy Volunteers | 130 | Dec 2026 | ≤ 134 d | 2026-06-25 |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesNCT06120075Number of Participants With Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: AB801, Docetaxel | Advanced Cancer | 91 | Nov 2026 | ≤ 103 d | 2026-08-13 |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095Overall survivalRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab | Advanced Upper Gastrointestinal Tract Adenocarcinoma | 1,040 | Aug 2026 | ≤ 12 d | 2026-07-31 |
| A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult ParticipantsNCT07641881Maximum observed concentration for casdatifanRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Casdatifan | Healthy Participants | 24 | 2026-07-03actual | — | 2026-08-13 |
| Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)NCT07364214Percentage of total radioactivity excreted in urine and fecesOpen-label · Basic science | Phase 1 | Completed | Drug: Quemliclustat | Healthy Participants | 8 | 2026-04-06actual | — | 2026-05-01 |
| Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)NCT06919991Area Under the Plasma Drug Concentration-Time Curve (AUC) for casdatifanOpen-label · Basic science | Phase 1 | Completed | Drug: Casdatifan, Itraconazole, Phenytoin | Healthy Participants | 14 | 2025-10-18actual | — | 2025-11-13 |
| An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.NCT04660812Cohort A and B - Progression-free Survival (PFS)Randomized · Single-masked · Treatment | Phase 1/2 | Completed | Drug: AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib | Metastatic Colorectal Cancer | 227 | 2025-09-05actual | — | 2025-10-20 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2025-08-25actual | — | 2025-08-28 |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856Objective response rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Domvanalimab, Etrumadenant, Zimberelimab | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 151 | 2025-07-09actual | — | 2026-06-15 |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesNCT03628677Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Domvanalimab, Zimberelimab | Solid Tumor, Unspecified, Adult | 75 | 2025-01-23actual | — | 2025-02-04 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerNCT03846310Percentage of participants with Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab | Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation | 77 | 2024-11-18actual | — | 2024-12-09 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerNCT04381832Objective Response Rate (ORR) in Stage 1 and 2Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant | 173 | 2024-08-30actual | — | 2025-07-22 |
| Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid TumorsNCT04087018Objective response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: zimberelimab | Advanced Solid Tumors | 18 | 2024-06-17actual | — | 2024-09-19 |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy VolunteersNCT06004921Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AB801, Placebo | Cancer | 32 | 2024-02-23actual | — | 2024-08-28 |
| A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult VolunteersNCT05999513Area Under the Plasma Drug Concentration-Time Curve (AUC)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: casdatifan | Healthy Participants | 24 | 2023-10-31actual | — | 2024-10-17 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy VolunteersNCT05117554Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: casdatifan, Placebo, Midazolam | Healthy Participants | 70 | 2023-02-17actual | — | 2024-10-17 |
| A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of CancerNCT05411146Excretion of total radioactivity in urineOpen-label · Basic science | Phase 1 | Completed | Drug: [14C]-etrumadenant | Healthy Participants | 8 | 2022-07-07actual | — | 2024-05-24 |
| A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult ParticipantsNCT05277012Maximum Observed Plasma Concentration (Cmax) of EtrumadenantRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etrumadenant | Healthy Participants | 24 | 2022-03-31actual | — | 2024-05-24 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult ParticipantsNCT05154136Maximum Observed Plasma Concentration (Cmax) of Etrumadenant Administered With or Without ItraconazoleOpen-label · Treatment | Phase 1 | Completed | Drug: Etrumadenant, Itraconazole | Healthy Participants | 20 | 2021-12-10actual | — | 2024-05-24 |
| A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersNCT04575311AB680 Peak Plasma Concentration (Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AB680 · Other: Placebo | Healthy Volunteers | 32 | 2021-09-22actual | — | 2024-05-24 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2021-08-18actual | — | 2024-05-24 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesNCT03719326Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP) | TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | 35 | 2021-07-01actual | — | 2024-05-24 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal MalignanciesNCT03720678Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: etrumadenant, mFOLFOX | GastroEsophageal Cancer, Colorectal Cancer | 44 | 2021-01-27actual | — | 2024-05-24 |
| A Study to Investigate the Safety of AB680 in Healthy VolunteersNCT03677973Number of Participants with Treatment Emergent Adverse Events (TEAEs).Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AB680 · Other: Placebo | Healthy Volunteers | 64 | 2019-08-19actual | — | 2024-05-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19